Clinical trial
Phase II Open 24 Weeks Study to Evaluate Effect and Safety of Tocilizumab as the First Line Therapy in Subjects With Polymyalgia Rheumatica (PMR)
NCT01713842 is registered in ClinicalTrials.gov with University Hospital, Brest as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase II Open 24 Weeks Study to Evaluate Effect and Safety of Tocilizumab as the First Line Therapy in Subjects With Polymyalgia Rheumatica (PMR)
- Lead sponsor
- University Hospital, Brest
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- July 31, 2012
- Completion date
- October 31, 2014
- Enrollment
- 21 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.